European Commission approves Array's encorafenib and binimetinib combo for melanoma treatment

European Commission approves Array's encorafenib and binimetinib combo for melanoma treatment

BOULDER -- Array BioPharma Inc . (NASDAQ: ARRY) today announced the European Commission (EC) has approved BRAFTOVI (encorafenib) in combination with MEKTOVI (binimetinib) for the treatment of... Read More

Friday September 21, 2018 0 comments Tags: Denver, Array BioPharma, Ron Squarer, encorafenib, binimetinib

Array BioPharma names Carrie S. Cox chair of its board of directors

Array BioPharma names Carrie S. Cox chair of its board of directors

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) today announced Carrie S. Cox has been named chair of its board of directors effective immediately. Cox has been appointed to the Audit and... Read More

Tuesday August 14, 2018 0 comments Tags: Boulder, Array BioPharma, Carrie Cox, Ron Squarer

Array BioPharma colorectal cancer drugs receive Breakthrough Therapy Designation from FDA

Array BioPharma colorectal cancer drugs receive Breakthrough Therapy Designation from FDA

BOULDER -- Array BioPharma Inc. (NASDAQ: ARRY) today announced it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for encorafenib (BRAFTOVI),... Read More

Tuesday August 7, 2018 0 comments Tags: Boulder, Array BioPharma, Victor Sandor, FDA

Array BioPharma: European Medicines Agency recommends approval of melanoma cancer drug

Array BioPharma: European Medicines Agency recommends approval of melanoma cancer drug

BOULDER -- Array BioPharma Inc. (NASDAQ: ARRY) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending... Read More

Monday July 30, 2018 0 comments Tags: Boulder, Array BioPharma, Ron Squarer

Array BioPharma: National Comprehensive Cancer Network, FDA OKs drug combo for melanoma

Array BioPharma: National Comprehensive Cancer Network, FDA OKs drug combo for melanoma

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) announced that the National Comprehensive Cancer Network (NCCN) has updated the Clinical Practice Guidelines in Oncology for Melanoma to include... Read More

Monday July 16, 2018 0 comments Tags: Boulder, Array BioPharma, melanoma, Ron Squarer, FDA

Array BioPharma announces FDA approval of encorafenib and binimetinib cancer drugs

Array BioPharma announces FDA approval of encorafenib and binimetinib cancer drugs

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) announced the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI(encorafenib) capsules in combination with MEKTOVI(binimetinib)tablets... Read More

Thursday June 28, 2018 0 comments Tags: Boulder, Array BioPharma, encorafenib, binimetinib, Ron Squarer

Array BioPharma reports positive survival results for melanoma drugs

Array BioPharma reports positive survival results for melanoma drugs

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) andFrance-based Pierre Fabreannounced results of a study of overall survival in patients with BRAF -mutant melanoma, indicating that treatment with... Read More

Wednesday February 7, 2018 0 comments Tags: Boulder, Array BioPharma, encorafenib, binimetinib, Victor Sandor

Array’s triplet drug combination found effective for colorectal cancer treatment

Array’s triplet drug combination found effective for colorectal cancer treatment

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) and Pierre Fabre today announced updated results from the 30 patient safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet... Read More

Monday January 22, 2018 0 comments Tags: Boulder, Array BioPharma, binimetinib, encorafenib, cetuximab, Pierre Fabre